Popular weight loss drugs are sending Americans to the ER

While millions of Americans have turned to popular weight loss drugs to shed pounds in recent years, taking them isn’t without some risks.

Now, research led by the scientists at the Centers for Disease Control and Prevention has found that tens of thousands of Americans have ended up in the emergency room after taking semaglutide: the active ingredient in GLP-1 drugs, including drugmaker Novo Nordisk’s Ozempic and Wegovy. The findings may be an indicator that more patient education is necessary when it comes to taking the drugs.

“We found that it’s very infrequent that semaglutide leads to very serious adverse events that would land a patient in the hospital, but that they do occur,” Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School, told Health.

Using national surveillance data collected at dozens of hospitals, they estimated that semaglutide had been a contributing factor in nearly 25,000 emergency room visits from 2022 to 2023. More than 82 percent of those visits occurred in 2023, and the reason was usually gastrointestinal complications. Patients experienced nausea, vomiting, stomach pain, and diarrhoea.

Some people also came into emergency rooms with allergic reactions and hypoglycemia, which is also known as low blood sugar. A handful of patients were diagnosed with pancreatitis and just four were diagnosed with biliary disease, which impacts the gallbladder.

Read full story

Source: The Independent, 1 May 2025